Accessibility Menu
 
Viking Therapeutics logo

Viking Therapeutics

(NASDAQ) VKTX

Current Price$35.54
Market Cap$4.10B
Since IPO (2015)+296%
5 Year+505%
1 Year+50%
1 Month-0%

Viking Therapeutics Financials at a Glance

Market Cap

$4.10B

Revenue (TTM)

$0.00

Net Income (TTM)

$359.64M

EPS (TTM)

$-3.18

P/E Ratio

-11.16

Dividend

$0.00

Beta (Volatility)

1.26 (Average)

Price

$35.54

Volume

2,486

Open

$35.45

Previous Close

$35.51

Daily Range

$34.85 - $35.66

52-Week Range

$22.96 - $43.15

VKTX: Motley Fool Moneyball Superscore

70

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Viking Therapeutics

Industry

Biotechnology

Employees

53

CEO

Brian Lian, PhD, MBA

Headquarters

San Diego, CA 92121, US

VKTX Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-47%

Return on Capital

-62%

Return on Assets

-50%

Earnings Yield

-8.96%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$4.10B

Shares Outstanding

115.55M

Volume

2.49K

Short Interest

0.00%

Avg. Volume

2.64M

Financials (TTM)

Gross Profit

$431.00K

Operating Income

$393.34M

EBITDA

$393.34M

Operating Cash Flow

$278.69M

Capital Expenditure

$0.00

Free Cash Flow

$278.69M

Cash & ST Invst.

$705.74M

Total Debt

$137.00K

Viking Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$94.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$4.10B

N/A

Market Cap/Employee

$91.18M

N/A

Employees

45

N/A

Net Income

$157.66M

-345.2%

EBITDA

$164.74M

-257.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$705.60M

-21.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

-100.0%

Short Term Debt

$137.00K

-72.0%

Return on Assets

-50.25%

N/A

Return on Invested Capital

-61.55%

N/A

Free Cash Flow

$85.29M

-173.5%

Operating Cash Flow

$85.29M

-173.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CRNXCrinetics Pharmaceuticals, Inc.
$39.02-1.89%
NAMSNewAmsterdam Pharma Company N.V.
$33.20-2.38%
LGNDLigand Pharmaceuticals Incorporated
$223.24-0.82%
AKROAkero Therapeutics, Inc.
$54.65+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PBMPsyence Biomedical
$5.87+1.04%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.07-0.02%
TQQQProShares Trust - ProShares UltraPro Qqq
$56.43+0.01%
SMRNuScale Power
$11.41-0.03%

Questions About VKTX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.